Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms-Reference-Cited by-同舟云学术

Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms

Published:2015-03 Issue:1-3 Volume:162 Page:169-174
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Schooler Nina R.,Buchanan Robert W.,Laughren Thomas,Leucht Stefan,Nasrallah Henry A.,Potkin Steven G.,Abi-Saab Danielle,Berardo Carmen Galani,Bugarski-Kirola Dragana,Blaettler Thomas,Edgar Chris J.,Nordstroem Anna-Lena,O'Gorman Cedric,Garibaldi George

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference51 articles.

1. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia;Alphs;Psychopharmacol. Bull.,1989

2. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations;Andreasen;Br. J. Psychiatry,1989

3. Remission in schizophrenia: proposed criteria and rationale for consensus;Andreasen;Am. J. Psychiatry,2005

4. Pharmacological approaches to treating negative symptoms: a review of clinical trials;Arango;Schizophr. Res.,2013

5. The burden of schizophrenia on caregivers: a review;Awad;Pharmacoeconomics,2008

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria;Schizophrenia Research;2024-09

2. The efficacy of homestyle rehabilitation on negative symptoms in chronic schizophrenia: A randomized controlled trial;Frontiers in Psychiatry;2023-04-17

3. Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study;Schizophrenia Research;2022-12

4. Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia;Brain, Behavior, and Immunity;2022-07

5. Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia;Patient Preference and Adherence;2022-07